Children's Hospital Medical Center, Cincinnati
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
Inclusion Criteria: * Body Mass Index over 35 * Type 2 Diabetes * Currently taking GLP01 RA agonist (for GLP 1 group) * Not taking GLP-1 RA agonist (for control group) Exclusion Criteria: * Diagnosis of gastroparesis * patient refusal to participate * Previous gastric bypass or any other gastric surgery * Currently on peritoneal dialysis * Abdominal pathology * Gastro-intestinal obstruction * Pregnancy
GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.